SCHEMBL2870417

SCHEMBL2870417

COc1cc(-n2nc3c(c2N)c(=O)[nH]c2cc(OCCCN4CCOCC4)ccc23)ccc1Oc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.43
FGFR1 P11362 1/20 0.43
KDR P35968 1/20 0.43
MCHR1 Q99705 5/20 0.42
KDM4E B2RXH2 1/20 0.42
CSF1R P07333 1/20 0.41
RAF1 P04049 2/20 0.40
MAP2K1 Q02750 2/20 0.40
MAPK3 P27361 1/20 0.40
MAPK1 P28482 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
MET P08581 1/20 0.40
HRH3 Q9Y5N1 1/20 0.39
KCNH2 Q12809 1/20 0.39
CHEK1 O14757 1/20 0.39
DRD2 P14416 1/20 0.39
DRD4 P21917 1/20 0.39
DRD3 P35462 1/20 0.39
MAOA P21397 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2865355 0.91 FGFR1 (0.43) PDGFRBFGFR1KDRKDM4ECSF1R
SCHEMBL2857971 0.91 FGFR1 (0.48) PDGFRBFGFR1KDRKDM4ECSF1R
SCHEMBL2860241 0.88 MAP2K1 (0.48) KDRKDM4ECSF1RRAF1MAP2K1
SCHEMBL2861337 0.88 KDM4E (0.50) PDGFRBFGFR1KDRKDM4ERXFP1
SCHEMBL2864303 0.85 FGFR1 (0.48) PDGFRBFGFR1KDRKDM4ECSF1R
SCHEMBL2868766 0.85 KDM4E (0.51) PDGFRBFGFR1KDRKDM4EDRD2
SCHEMBL2869046 0.84 RAF1 (0.47) PDGFRBFGFR1KDRMCHR1KDM4E
SCHEMBL2866809 0.84 MCHR1 (0.51) PDGFRBFGFR1KDRMCHR1KDM4E
SCHEMBL2866686 0.84 CSF1R (0.45) PDGFRBFGFR1KDRKDM4ECSF1R
SCHEMBL2865177 0.83 FGFR1 (0.45) PDGFRBFGFR1KDRKDM4EHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 PDGFRB 375/4885FGFR1 201/4885KDR 1226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.